BioHorizons has launched Prolifica™, an allogeneic growth factor designed for bone healing and tissue regeneration. This product features a biphasic release of proteins to support the healing process and retains at least 16 proteins associated with cell growth and bone healing.
Background
The introduction of Prolifica™ addresses the demand for advanced allograft solutions in hard tissue regenerative procedures. The product's formulation aims to enhance outcomes in bone grafting procedures, both standalone and in combination with other graft materials.
Data Highlights
No numerical data or trial results are provided in the source material.
Key Findings
Prolifica™ contains a blend of allogeneic growth factors that support bone healing.
The product features a biphasic release profile for proteins and growth factors.
It retains a minimum of 16 proteins relevant to cell growth and tissue regeneration.
Prolifica can be used in standalone bone grafting or in combination with autologous bone.
BioHorizons aims to provide solutions for complex regenerative procedures due to the aging population.
Clinical Implications
Prolifica™ is a new option for bone healing and tissue regeneration in grafting scenarios.
Conclusion
The launch of Prolifica™ by BioHorizons adds to the biomaterials portfolio for bone regeneration.
